A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Recruiting · Phase 3 · NCT06646276
Conditions: Extensive-Stage Small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $513
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 530
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- BMS-986489 (Atigotatug+Nivolumab) (biological), Atezolizumab (biological), Carboplatin (drug), Etoposide (drug)
- Dates
- Started 2025-02-25; completion 2031-07-14
- Results posted
- Not yet
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
From ClinicalTrials.gov, last updated 2026-10-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $513 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael W. Meshad, MD Medical Oncology · Mobile, AL
- Allison P. Watson Hematology & Oncology · Sioux Falls, SD
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Coastal Pharmacy, Llc $412
- Sanford Cancer Center $101
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.